Search clinical trials for: Edaravone Dexborneol

Total 56 results

Hui-Sheng Chen

Completed

Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

Stroke | Endovascular Thrombectomy

China
Lili Cao

Recruiting

Protective Effects of Edaravone Dexborneol

Acute Ischemic Stroke

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke

Stroke

China
Beijing Tiantan Hospital

Completed

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Acute Ischemic Stroke | Mechanical Thrombectomy | Edaravone Dexborneol | Phase III

China
Xiangya Hospital of Central South University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke (EARLYS)

Ischemic Stroke, Acute | Treatment Outcome

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows (EXISTENT)

Stroke, Ischemic

China
Huashan Hospital
Shanghai Stroke Association

Not yet recruiting

Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

Stroke, Ischemic
Xuanwu Hospital, Beijing

Recruiting

Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke (EXPAND)

Acute Ischemic Stroke

China
Simcere Pharmaceutical Co., Ltd

Not yet recruiting

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Post-stroke Cognitive Impairment

China
Simcere Pharmaceutical Co., Ltd

Not yet recruiting

The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS

Subjects With Acute Ischemic Stroke
First Affiliated Hospital, Sun Yat-Sen University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage (ED-ICH)

Intracerebral Hemorrhage
The Second Hospital of Hebei Medical University

Recruiting

Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol (TASPE)

Acute Ischemic Stroke

China
Auzone Biological Technology Pty Ltd

Completed

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

Healthy Adult Subjects

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

China
Nanjing Yoko Biomedical Co., Ltd.

Completed

Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

Pharmacokinetics

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Compound Edaravone Injection for Acute Ischemic Stroke

Acute Ischemic Stroke

China
Nanjing Yoko Biomedical Co., Ltd.

Suspended

Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

China
Nanjing Yoko Biomedical Co., Ltd.

Completed

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

Drug-drug Interaction

China
Kumamoto University
Japan Heart Foundation

Completed

Pilot Study of Edaravone to Treat Acute Myocardial Infarction

Myocardial Infarction | Reperfusion Injury

Japan
Auzone Biological Technology Pty Ltd
TIGERMED AUSTRALIA PTY LIMITED; CMAX Clinical Research Pty Ltd

Completed

A Study of TTYP01 in Healthy Adult Subjects

Healthy Adult Subjects

Australia
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States, Canada, Japan, France, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Terminated

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Canada, Japan, Germany, Korea, Republic of, Switzerland
Yantai YenePharma Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet

Intracranial Hemorrhages | Stroke, Acute

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Canada, Japan, France, Germany, Italy
Mitsubishi Tanabe Pharma America Inc.

Terminated

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

ALS

United States, Korea, Republic of, Canada, Germany, Japan, Italy, Switzerland
Xijing Hospital
First Affiliated Hospital Xi'an Jiaotong University

Unknown

Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients (I/R)

Kidney Transplantation
Mitsubishi Tanabe Pharma America Inc.
Massachusetts General Hospital

Active, not recruiting

Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

Amyotrophic Lateral Sclerosis | ALS

United States, Canada
Treeway B.V.

Recruiting

ASURE: Alzheimer Study Using oRal Edaravone

Alzheimer Disease

Croatia, Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Japanese Patients With ALS

Japan
First Affiliated Hospital of Guangxi Medical University

Recruiting

Edaravone in the Treatment of Aquaporin-4 Antibody-positive Optic Neuritis

Optic Neuritis

China
Mitsubishi Tanabe Pharma Corporation

Completed

Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric Tube

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Acute Ischemic Stroke (AIS)

Netherlands, Finland, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Japanese Patients With ALS

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)

Healthy Adult Subjects

Japan
Combination Therapy for Acute Ischemic Stroke Study...
Japan Cardiovascular Research Foundation

Completed

Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke (EAST)

Stroke

Japan
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Healthy | Hepatic Impairment

Japan
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

Healthy | Renal Impairment

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Study of Oral Edaravone in Healthy Adult Males

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Cerebral Infarction
Isfahan University of Medical Sciences

Unknown

Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)

Neuromuscular Diseases

Iran, Islamic Republic of
Ruijin Hospital

Not yet recruiting

The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS

Amyotrophic Lateral Sclerosis | Respiratory Function | Scopolamine

China
Mitsubishi Tanabe Pharma Corporation

Terminated

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Acute Ischemic Stroke

Japan

Search clinical trials for: Edaravone Dexborneol

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations